Last reviewed · How we verify

NCT03770117: SIPUP

Study of the Effect of Prehabilitation on Markers of Sarcopenia in Patients Undergoing Pancreatoduodenectomy for Malignant Disease

Completed Last updated 19 January 2021
What this trial tests

trial testing Prehabilitation in Pancreatic Ductal Adenocarcinoma in 113 participants. Completed in 1 July 2019.

Timeline
4 October 2018
Primary endpoint
1 July 2019
1 July 2019

Quick facts

Lead sponsorManchester University NHS Foundation Trust
StatusCompleted
Study typeOBSERVATIONAL
Enrollment113
Start date4 October 2018
Primary completion1 July 2019
Estimated completion1 July 2019
Sites1 location across United Kingdom

Drugs / interventions tested

Conditions studied

Sponsor

Manchester University NHS Foundation Trust

Who can join

Adults 16 to 100, any sex, with Pancreatic Ductal Adenocarcinoma. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The aim of this study is to assess whether prehabilitation supervised by an appropriate multimodality team improves indices of sarcopenia in patients scheduled to undergo pancreatoduodenectomy.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other trials of Prehabilitation

Trials testing the same drug.

Other recruiting trials for Pancreatic Ductal Adenocarcinoma

Currently open trials in the same condition.

Other Manchester University NHS Foundation Trust trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03770117.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing